Dissociation between IFN-alpha-induced anti-viral and growth signaling pathways.
The ability of IFN-alpha to induce an anti-viral state in a wide variety of cell types as well as to inhibit cellular growth has long been appreciated. It is less clear, however, whether both these effects lie downstream of a common signaling pathway. In this study we have taken advantage of an atypical human myeloma cell line (KAS-6/1) displaying a dramatic proliferative response to IFN-alpha in an effort to resolve the signaling requirements for IFN-alpha-induced anti-viral and growth regulatory effects. Thus, we have analyzed the ability of IFN-alpha to induce a number of known receptor-initiated events in this cell line and have compared these responses with those exhibited by a cell lineage- and maturation stage-matched myeloma cell line (ANBL-6) that displays typical IFN-alpha responsiveness. Despite the widely contrasting effects of IFN-alpha on cellular proliferation, IFN-alpha was shown to be comparable in its ability to induce the expression of early response genes as well as induce resistance to viral infection in both cell lines. By contrast, the effects of IFN-alpha on the activation of mitogen-activated protein kinase (MAPK) were strikingly distinct. Finally, although inhibition of MEK and MAPK activation had no effect on the induction of the anti-viral response, it completely blocked IFN-alpha-stimulated proliferation of the KAS-6/1 cells. In summary, our analysis of the role of the MAPK and anti-viral signaling pathways using these two cell lines suggests that the anti-viral and growth regulatory effects of IFN-alpha display a differential requirement for activation of the MAPK pathway.
Arora
T
T
Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA.
Floyd-Smith
G
G
Espy
M J
MJ
Jelinek
D F
DF
D015088:2',5'-Oligoadenylate Synthetase / Q000378:metabolism; D000998:Antiviral Agents / Q000276:immunology / Q000502:physiology*; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D002454:Cell Differentiation / Q000276:immunology; D002455:Cell Division / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000276:immunology; D004789:Enzyme Activation / Q000276:immunology; D005419:Flavonoids / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000276:immunology; D006131:Growth Inhibitors / Q000276:immunology / Q000502:physiology*; D006801:Humans; D007113:Immunity, Innate; D016898:Interferon-alpha / Q000378:metabolism / Q000502:physiology*; D048369:MAP Kinase Kinase 1; D008565:Membrane Proteins; D020929:Mitogen-Activated Protein Kinase Kinases; D009101:Multiple Myeloma / Q000201:enzymology / Q000276:immunology / Q000473:pathology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D053633:Receptor, Interferon alpha-beta; D017471:Receptors, Interferon / Q000096:biosynthesis; D015398:Signal Transduction / Q000235:genetics / Q000276:immunology*; D014407:Tumor Cells, Cultured
D000998:Antiviral Agents; D005419:Flavonoids; D006131:Growth Inhibitors; D016898:Interferon-alpha; D008565:Membrane Proteins; D017471:Receptors, Interferon; D053633:Receptor, Interferon alpha-beta; D011505:Protein-Tyrosine Kinases; D017346:Protein Serine-Threonine Kinases; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D048369:MAP Kinase Kinase 1; C482125:MAP2K1 protein, human; D020929:Mitogen-Activated Protein Kinase Kinases; D015088:2',5'-Oligoadenylate Synthetase; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one